Skip to content
    Ysios Capital logo

    Ysios Capital

    San Sebastián, SpainFounded 2008
    ysioscapital.comLinkedIn
    Biotech & Life SciencesHealthcare

    Ysios Capital is a leading European venture capital firm specialized in the life sciences and biotechnology sector, financing highly innovative companies developing novel therapies for indications with high unmet medical needs. Founded in 2008, it is the largest life sciences venture capital firm in Spain with offices in San Sebastián and Barcelona.

    54% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Their most common stage is series-b (40% of deals). Average disclosed round size is $77.9M (across 36 rounds with reported amounts).

    Find people at Ysios Capital on Goldilocks AI

    Portfolio

    42

    Fund Size

    $260M

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    JP

    Joan Perelló Bestard

    Managing Partner

    KW

    Karen Wagner

    General Partner

    AU

    Arturo Urrios

    Partner

    CD

    Claudia D'Augusta

    Venture Partner

    JX

    Jordi Xiol

    Partner

    LB

    Lance Berman

    Venture Partner

    RM

    Raúl Martín-Ruiz

    Partner

    TH

    Thomas Harth

    Partner

    MR

    Malgorzata Rogalska

    Investment Professional (Sourcing and Diligence)

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    65 investments
    CompanyRoundAmountDate
    Kynexis logoKynexisSeries A—Aug 2026
    Adcendo ApS logoAdcendo ApSSeries C$75MApr 2026
    SpliceBio logoSpliceBioSeries B$135MJun 2025
    SSplice BioSeries B$135MJun 2025
    ReproNovo logoReproNovoSeries A$65MMay 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Neurona logoNeuronaSeries A$102MJan 2025
    Anaconda logoAnacondaSeries C$150MJan 2025
    Adcendo ApS logoAdcendo ApSSeries B$135MNov 2024
    MMemo Therapeutics AGSeries C—May 2024
    Engrail Therapeutics logoEngrail TherapeuticsSeries B$157MMar 2024
    EEngrailSeries B$157MMar 2024
    Adcendo ApS logoAdcendo ApSSeries B$135MJan 2024
    Tagworks Pharmaceuticals logoTagworks PharmaceuticalsSeries A$65MJun 2023
    TTagworksSeries A$64MJun 2023
    SparingVision logoSparingVisionSeries B—Sep 2022
    MMineralysSeries B$118MJun 2022
    SpliceBio logoSpliceBioSeries A—Feb 2022
    MMineralysSeries B$118MJan 2022
    MMineralys Therapeutics, Inc.Series B$118MJan 2022
    NNorthSea TherapeuticsSeries C$80MDec 2021
    Cytoki Pharma logoCytoki PharmaSeries A$45MMay 2021
    Adcendo ApS logoAdcendo ApSSeries A$17.3MApr 2021
    CCorWave SASeries B$42.5MJan 2021
    Adcendo ApS logoAdcendo ApSSeries B$135MJan 2021
    Page 1 of 3

    Top Co-Investors

    Gilde Healthcare14 shared
    Forbion13 shared
    Bpifrance10 shared
    Asabys Partners10 shared
    Kurma Partners10 shared
    Sunstone Life Science Ventures10 shared
    Seventure Partners9 shared
    Roche Venture Fund9 shared
    HealthCap9 shared
    Novo Capital9 shared
    RA Capital Management9 shared
    Novartis Venture Fund8 shared
    Andera Partners8 shared
    Sunstone Partners8 shared
    M Ventures8 shared
    OrbiMed8 shared
    Columbus Venture Partners7 shared
    Caixa Capital Risc7 shared
    HBM Healthcare Investments7 shared
    New Enterprise Associates6 shared

    Last updated: 20 October 2026